Ianalumab
Ianalumab
Ianalumab (pronunciation: ee-an-al-u-mab) is a biopharmaceutical drug that is currently under investigation for its potential therapeutic applications.
Etymology
The name 'Ianalumab' follows the World Health Organization's (WHO) guidelines for the nomenclature of monoclonal antibodies. The suffix '-mab' indicates that the drug is a monoclonal antibody. The infix '-alu-' suggests that the drug targets the immune system, while the prefix 'Ian-' does not carry a specific meaning and is used for distinction.
Therapeutic Applications
Ianalumab is being studied for its potential use in the treatment of various autoimmune diseases. It works by targeting and inhibiting the B cell activating factor (BAFF), which plays a crucial role in the survival and maturation of B cells. By inhibiting BAFF, Ianalumab can potentially reduce the number of harmful B cells in autoimmune diseases.
Clinical Trials
Several clinical trials have been conducted to evaluate the safety, efficacy, and pharmacokinetics of Ianalumab in patients with autoimmune diseases. The results of these trials are crucial in determining the future clinical use of this drug.
Related Terms
- Monoclonal Antibodies
- Autoimmune Diseases
- B cell activating factor (BAFF)
- Clinical Trials
- Pharmacokinetics
External links
- Medical encyclopedia article on Ianalumab
- Wikipedia's article - Ianalumab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski